Janus Henderson Group plc 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 2:58 pm Sale |
2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
JANUS HENDERSON GROUP PLC JHG |
32,180 0.000% |
-5,059,105 (-99.37%) |
Filing |
| 2023-02-10 11:50 am Purchase |
2022-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
JANUS HENDERSON GROUP PLC JHG |
5,091,285 7.900% |
1,075,127 (+26.77%) |
Filing |
| 2022-02-10 5:22 pm Sale |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
JANUS HENDERSON GROUP PLC JHG |
4,016,158 6.600% |
-67,395 (-1.65%) |
Filing |
| 2021-02-12 3:48 pm Purchase |
2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
JANUS HENDERSON GROUP PLC JHG |
4,083,553 8.000% |
4,083,553 (New Position) |
Filing |